Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Komal Jhaveri, L.D. Eli, Hans Wildiers, Sara A. Hurvitz, Ángel Guerrero‐Zotano, Nisha Unni, Adam Brufsky, H. Park, James Waisman, Eddy S. Yang, Iben Spanggaard, Sonya Reid, Mark E. Burkard, S Vinayak, Aleix Prat, Mónica Arnedos, François‐Clément Bidard, Sherene Loi, John Crown, Manali Bhave, Sarina A. Piha‐Paul, Jennifer M. Suga, Stephen Chia, Cristina Saura, José Á. García-Sáenz, Valentina Gambardella, M.J. de Miguel, Einav Nili Gal‐Yam, A. Raphael, Salomon M. Stemmer, X. Cynthia, Ariella B. Hanker, D. Ye, Jonathan W. Goldman, Ron Bose, Lanell M. Peterson, Joshua S. K. Bell, A. Lindsay Frazier, D. DiPrimeo, Alvin Wong, Carlos L. Arteaga, David B. Solit